GlaxoSmithKline plc's (LON: GSK) majority-owned ViiV Healthcare has seen positive results from two Phase III studies investigating its two-drug HIV treatment, Proactive Investors reported on Thursday.
The current standard treatment involves a three-drug regimen of dolutegravir and two nucleoside reverse transcriptase inhibitors.
However, results from the GEMINI-1 and GEMINI-2 studies show a two-drug regimen of dolutegravir and lamivudine is just as effective.
The studies were designed to evaluate the safety and efficacy of the two-drug regimen compared to the standard three-drug regimen. Both GEMINI-1 and GEMINI-2 met their primary endpoint for non-inferiority, a standard measure of HIV control, at Week 48.
ViiV plans to submit for regulatory approval for the two-drug regimen later this year. Full results from the studies will be presented at an upcoming meeting.
Kromek collaborates on next-gen CT detector technology
Gilead Sciences initiates Phase 2 trial in Europe to evaluate lenacapavir for HIV prevention
European Commission grants authorisation to ViiV Healthcare's Apretude for prevention of HIV
Celanese to supply VitalDose drug delivery platform for Population Council's MPT Intravaginal Ring
Henry Schein introduces equipment repair subscription - Henry Schein Thrive Service Plus
Seres Therapeutics provides business updates and reports Q2 2023 financial results